Non-alcoholic fatty liver disease (NAFLD) is a complication of metabolic syndrome and represents a spectrum of progressive liver pathologies, from simple steatosis to inflammatory non-alcoholic steatohepatitis (NASH). An estimated 25% of the American population has NAFLD and it is projected to dramatically in- crease within the next decade following the upward trend of the obesity epidemic. Activation of the metabolic regulator sirtuin-1 (SirT1), an NAD+-dependent class III histone deacetylase, can improve NAFLD. SirT1 is believed to activate beneficial metabolic processes similar to those triggered by caloric restriction and is an important regulator of hepatic lipid metabolism. Conversely, inhibition of SirT1 can promote NAFLD, as seen in mice with metabolic syndrome. In my laboratory, we have found that reversible oxidative protein adducts, including glutathione (GSH) inhibit SirT1 under these conditions. Glutaredoxin-1 (Glrx) is a thioltransferase that preferentialy removes protein GSH-adducts. Chow fed Glrx knockout mice Glrx-/-, develop obesity, hyperlipidemia, and fatty liver, which progresses to NASH upon high fat, high sucrose feeding. In these mice, upregulation of hepatic lipid synthesis was concomitant with inhibition of SirT1 by reversible glutathione adducts. Reconstitution of Glrx in the liver of Glrx-/- mice restored SirT1 activity, reversing fatty liver. To determine whether the metabolic consequences of Glrx-deficiency were truly mediated by SirT1, we overexpressed a novel, oxidant-resistant SirT1 triple cysteine mutant (C67S, C318S, C613S) in Glrx-deficient cells. Expression of our constitutively active SirT1 suppressed lipid synthesis. My central hypothesis is that the redox-regulation of Glrx and SirT1 is instrumental for hepatic lipid homeostasis. Sustained GSH-protein adducts caused by oxidative stress perturb hepatic lipid metabolism, lea ding to lipid accumulation in the liver and plasma, and eventually to metabolic syndrome. Similar effects are caused by Glrx ablation, which sustains oxidative inhibition of SirT1 promoting hepatic lipid accumulation. Based on my hypothesis and data I will study the following specific aims: #1: To determine the novel role of Glrx in regulating hepatic lipid metabolism. #2: To determine the role of SirT1 GSH adducts in regulating hepatic lipid metabolism. #3: To determine the extent to which Glrx or oxidant-resistant SirT1 mutant reverses NASH in mice with metabolic syndrome.

Public Health Relevance

Fatty liver disease often occurs with obesity, diabetes and metabolic disease and is projected to dramatically increase following the upward trend of the obesity epidemic. Unexpectedly, a specific genetic mouse model to study the regulation of liver protein function by oxidants develops a build-up of fat in the blood and liver. Thus, we will use this mouse model to investigate what role oxidants play in the development of fatty liver disease and if the build-up of fats can be stopped by gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK103750-04
Application #
9459350
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Teff, Karen L
Project Start
2015-07-01
Project End
2020-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
Yoon, Soonsang; Beermann, Mary Lou; Yu, Bryant et al. (2018) Aberrant Caspase Activation in Laminin-?2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity. J Neuromuscul Dis 5:59-73
Taylor, Erik; Huang, Nasi; Bodde, Jacob et al. (2018) MRI of atherosclerosis and fatty liver disease in cholesterol fed rabbits. J Transl Med 16:215
Anathy, Vikas; Lahue, Karolyn G; Chapman, David G et al. (2018) Reducing protein oxidation reverses lung fibrosis. Nat Med 24:1128-1135
Luptak, Ivan; Sverdlov, Aaron L; Panagia, Marcello et al. (2018) Decreased ATP production and myocardial contractile reserve in metabolic heart disease. J Mol Cell Cardiol 116:106-114
Vikram, Ajit; Lewarchik, Christopher M; Yoon, Jin-Young et al. (2017) Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel. Nat Med 23:361-367
Egea, Javier; Fabregat, Isabel; Frapart, Yves M et al. (2017) European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol 13:94-162
Shao, Di; Han, Jingyan; Hou, Xiuyun et al. (2017) Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1. Antioxid Redox Signal 27:313-327
Kumar, Santosh; Kim, Young-Rae; Vikram, Ajit et al. (2017) Sirtuin1-regulated lysine acetylation of p66Shc governs diabetes-induced vascular oxidative stress and endothelial dysfunction. Proc Natl Acad Sci U S A 114:1714-1719
Gorelenkova Miller, Olga; Behring, Jessica Belle; Siedlak, Sandra L et al. (2016) Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease. Antioxid Redox Signal 25:967-982
Watanabe, Yosuke; Murdoch, Colin E; Sano, Soichi et al. (2016) Glutathione adducts induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1? and improve limb revascularization. Proc Natl Acad Sci U S A 113:6011-6

Showing the most recent 10 out of 17 publications